Allied Biotech Balance Sheet Health
Financial Health criteria checks 4/6
Allied Biotech has a total shareholder equity of NT$1.2B and total debt of NT$771.1M, which brings its debt-to-equity ratio to 66%. Its total assets and total liabilities are NT$2.1B and NT$910.1M respectively. Allied Biotech's EBIT is NT$88.7M making its interest coverage ratio -33.2. It has cash and short-term investments of NT$724.8M.
Key information
66.0%
Debt to equity ratio
NT$771.07m
Debt
Interest coverage ratio | -33.2x |
Cash | NT$724.77m |
Equity | NT$1.17b |
Total liabilities | NT$910.12m |
Total assets | NT$2.08b |
Recent financial health updates
These 4 Measures Indicate That Allied Biotech (GTSM:1780) Is Using Debt Reasonably Well
Mar 05Is Allied Biotech (GTSM:1780) A Risky Investment?
Nov 25Recent updates
Is Allied Biotech Corporation (GTSM:1780) A Good Dividend Stock?
Apr 16These 4 Measures Indicate That Allied Biotech (GTSM:1780) Is Using Debt Reasonably Well
Mar 05Allied Biotech (GTSM:1780) Has Compensated Shareholders With A Respectable 49% Return On Their Investment
Jan 24Is Allied Biotech Corporation (GTSM:1780) At Risk Of Cutting Its Dividend?
Jan 03A Look At The Intrinsic Value Of Allied Biotech Corporation (GTSM:1780)
Dec 13Is Allied Biotech (GTSM:1780) A Risky Investment?
Nov 25Financial Position Analysis
Short Term Liabilities: 1780's short term assets (NT$1.5B) exceed its short term liabilities (NT$828.7M).
Long Term Liabilities: 1780's short term assets (NT$1.5B) exceed its long term liabilities (NT$81.4M).
Debt to Equity History and Analysis
Debt Level: 1780's net debt to equity ratio (4%) is considered satisfactory.
Reducing Debt: 1780's debt to equity ratio has increased from 42.3% to 66% over the past 5 years.
Debt Coverage: 1780's debt is not well covered by operating cash flow (17.8%).
Interest Coverage: 1780 earns more interest than it pays, so coverage of interest payments is not a concern.